[The first antidote is available].
.
Martin
M
Bischoff
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D000069604:Dabigatran / Q000009:adverse effects* / Q000037:antagonists & inhibitors*; D006801:Humans; D007262:Infusions, Intravenous
D061067:Antibodies, Monoclonal, Humanized; C000594745:idarucizumab; D000069604:Dabigatran